From Name:
From Email:
To Name:
To Email:

Optional Message:


FDA approves lenvatinib for advanced renal cell carcinoma

from Medscape

The U.S. Food and Drug Administration has approved lenvatinib , in combination with everolimus, for the treatment of patients with advanced renal cell carcinoma who were previously treated with an anti-angiogenic therapy, the company announced. Lenvatinib, a multiple receptor tyrosine kinase inhibitor, was approved for refractory differentiated thyroid cancer last year. more


Powered by MultiBriefs
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063